Investment
Features
FeesSafety
Academy
More
Pluang+

Compare REX AI Equity Premium Income ETF (AIPI) vs Cassava Sciences Inc (FLNA) Price & Performance

REX AI Equity Premium Income ETFTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

REX AI Equity Premium Income ETF vs Cassava Sciences Inc — how do they compare? REX AI Equity Premium Income ETF trades at $37.35, while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: REX AI Equity Premium Income ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

AIPIFLNA
Sector
Income / Options OverlayHealth
52-Week High
$44.93$4.64
52-Week Low
$32.45$0.87
Market Cap
$47.75M
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

REX AI Equity Premium Income ETF

AIPI (REX AI Equity Premium Income ETF) trades at $37.41 with minimal daily movement (+0.19%). The ETF employs an option-writing strategy focused on AI-related equities, generating substantial weekly dividends averaging $0.24-0.26 per distribution. Technical indicators show mixed signals with bullish moving averages but overbought RSI levels. The fund's unique structure provides high income but faces sustainability concerns if AI market momentum falters.

AIPI offers exceptional yield potential through its weekly distribution model but carries structural risks including potential NAV erosion. The ETF's performance depends heavily on continued AI sector strength and effective options management. Investors should weigh the high income against the fund's capped upside and concentration in technology stocks during market volatility.

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Returns comparison

Trailing returns across standard periods

About REX AI Equity Premium Income ETF

AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.

Read more on AIPI

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA